A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis

Journal of Clinical Psychiatry

Volumn 67, Issue 10, 2006, Pages 1511-1521

  Crespo Facorro, Benedicto ^a   Pérez Iglesias, Rocío ^a   Ramirez Bonilla, MariLuz ^a   Martínez García, Obdulia ^a   Llorca, Javier ^b   Vázquez Barquero, José Luis ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; HALOPERIDOL; LORMETAZEPAM; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; AMENORRHEA; ARTICLE; ASTHENIA; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERSALIVATION; HYPOKINESIA; HYPOSALIVATION; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP TIME; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN;

EID: 33751209463     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1004     Document Type: Article

References (47)

1. Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry Suppl 1998;172:53-59
2. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: rationale and hypothesis. J Clin Psychiatry 1996; 57(suppl 11):68-71
3. Robinson DG, Woerner MG, Alvir JMJ, et al. Predictors of treatment response from the first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549
4. May PR, Tuma AH, Dixon WJ, et al. Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981;38: 776-784
5. Sheitman BB, Lee H, Strous R, et al. The evaluation and treatment of first-episode psychoses. Schizophr Bull 1997;23:653-661
6. Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156: 79-87
7. Emsley RA (Risperidone Working Group). Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 1999;25:721-729
8. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-1404
9. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of antipsychotics in acute schizophrenia: a controlled study of the antipsychotic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-745
10. Chatterjee A, Chakos MH, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-1729
11. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231-238
12. Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005;65:1113-1138
13. Lambert M, Conus P, Lambert T, et al. Pharmacotherapy of first-episode psychosis. Expert Opin Pharmacother 2003;4:1-34
14. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomised controlled trials. Schizophr Res 1999;35:51-68
15. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
16. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomised trials. Am J Psychiatry 2001;158:518-526
17. Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994;382:11-15
18. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836-846
19. Rabinowitz J, Bromet E, Davidson M. Are patients enrolled in first episode psychosis drug trials representative of those treated in routine clinical practice? Schizophr Res 2003;61:149-155
20. Zerhouni E. Medicine: the NIH roadmap. Science 2003;302:63-72
21. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Ia: University of Iowa; 1984
22. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2001
23. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
24. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication ADM 76-338. Washington, DC: National Institute of Mental Health; 1976:217-222
25. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Ia: University of Iowa; 1983
26. Miller IW, Bishop S, Norman WH, et al. The modified Hamilton Rating Scale for Depression: reliability and validity. Psychiatry Res 1985;14: 131-142
27. Addington D, Addington J, Malika-Tyndale E. Assessing depression in schizophrenia: The Calgary Depression Scale. Br J Psychiatry Suppl 1993;22:39-44
28. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-433
29. Lingjarde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in antipsychotic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100
30. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
31. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare Publication (ADM) 76-338. Washington, DC: National Institute of Mental Health; 1976:534-537
32. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
33. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-953
34. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
35. Volavka J, Czobor P, Sheitman, B, et al. Clozapine, olanzapine, risperidone and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159: 255-262
36. Assessing the effects of atypical antipsychotics on negative symptoms: collaborative working group on clinical trial evaluations. J Clin Psychiatry 1998;59(suppl 12):28-34
37. Kopelowicz A, Zarate R, Tripodis K, et al. Differential efficacy of olanzapine for deficit and non-deficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157:987-993
38. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
39. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
40. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
41. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128
42. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31
43. Oosthuizen P, Emsley RA, Turner J, et al. Determining the optimal doses of haloperidol in first-episode psychosis. J Psychopharmacol 2001;15: 251-255
44. Tauscher J, Kapur S. Choosing the right doses of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 2001; 15:671-678
45. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10
46. Zhang-Wong J, Zipursky RB, et al. Optimal haloperidol dosage in first-episode psychosis. Can J Psychiatry 1999;44:164-167
47. Kane JM, Leucht S, Carpenter D, et al. Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders: introduction, methods, commentary, and summary. J Clin Psychiatry 2003;64(suppl 12):5-19